Cellipont Bioservices
Madhavi Anumula has extensive work experience in the biotech and pharmaceutical industry. Madhavi is currently serving as the VP of Product Development at Cellipont Bioservices, a position they assumed in May 2023. Prior to this, Madhavi held various roles at Catalent Pharma Solutions, including Director of Product Development (P&AD and MSAT), US Cell Therapy from December 2021 to May 2023, and Director of Process Development from October 2019 to December 2021. Madhavi also worked at Bellicum Pharmaceuticals, Inc., where they served as Associate Director of Process Development from May 2019 to October 2019, Manager of Process Development from January 2018 to April 2019, and Process Development Scientist II from April 2015 to December 2017. Before that, Madhavi worked at Cellerant Therapeutics as Senior Research Associate II from January 2013 to March 2015, Senior Research Associate I from January 2009 to January 2013, and Research Associate II from August 2005 to January 2009. Madhavi began their career at Bexel Pharmeceuticals as a Research Associate from April 2004 to August 2005.
Madhavi Anumula obtained a Master of Science degree in Biology from Georgia State University. Madhavi attended the university from 2002 to 2003.
This person is not in any offices
Cellipont Bioservices
Cellipont Bioservices is a cell therapy CDMO with more than 15 years’ experience in the development and small-to-large batch manufacturing of cell therapies. Our leaders have played an instrumental role in shaping cell therapy development and manufacturing methods and technologies, and our technically-strong team has been recognized by customers and technology partners for its ability to productively grow challenging cells. Cellipont is driven to help our clients to expand patient access to life-changing medicines through best-in-class development, analytical and manufacturing capabilities. We are a small company with a culture that is extremely responsive and customer-centric. Despite our size, Cellipont Bioservices has very deep technical experience, including 18,000+ tissue samples and more than 900 primary cell cultures. With decades of experience at advanced therapy service companies large and small, our leadership team is guiding Cellipont’s growth with deep knowledge of what it takes succeed in this space. Cellipont Bioservices facilities and quality systems are GMP-compliant and we hold a California Food & Drug Branch manufacturing license. We have extensive experience in multiple product areas, including CAR-T, iNK, dendritic cell, & other novel cell therapy approaches. OUR NAME: By combining “cell” with the latin root for bridge (pont), the name Cellipont Bioservices reflects several dimensions of what we are all about: we bridge our innovator clients with patients; we bridge technical excellence and personal service; and for our team, we bridge personal passion with professional vocation. As we finalize our corporate rebranding, we look forward to launching a new website in the coming weeks to better share our vision with you.